Is Alzheimer-related agitation becoming overwhelming?

Is someone you care for with Alzheimer's dementia exhibiting excessive motor activity, verbal and/or physical aggression? They may qualify for the ASPECT™ clinical research study that may help manage agitation.

Learn more

We believe in the power of research

But we can't make it happen on our own. We need the help of people affected by Alzheimer's to join clinical trials to complete recent breakthroughs.

Learn about Clinical Trials Join Us

Help us complete the investigational treatment for agitation associated with Alzheimer’s dementia

 

Agitation associated with Alzheimer’s dementia can be difficult and unpredictable to manage, as well as very challenging for patients and their loved ones. Examples of some easily identifiable agitated behaviors are 4:

Restlessness, pacing/aimless wandering, resistiveness.

Screaming, shouting, hitting others or self, throwing things, pushing people, hurting self or others.

Constant unwarranted requests for attention or help, tearing things or destroying property.

Source:
4 Cummings J, et al. Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. International Psychogeriatrics. 2015;27:7-17

We want to understand and treat these behaviors as much as you do. 

That is why in the  ASPECT study, an investigational drug called AVP-786 will be compared to placebo in patients with agitation associated with Alzheimer’s dementia. Researchers want to find out if this investigational drug is safe and effective (useful) in managing agitation in patients with Alzheimer’s dementia.

To be eligible for this study, a potential participant must:

Nurse helping senior patient in exercising with resistance band in clinic
  • Be between the ages of 50 and 90 [inclusive]
  • Have a diagnosis of probable Alzheimer’s dementia
  • Have moderate-to-severe agitation that interferes with their daily life
  • Have a reliable caregiver who spends a minimum of 2 hours per day, 4 days per week with them and is willing and able to comply with all study procedures

Benefits of Participating in the Alzheimer's Clinical Trial

Diagnosis - Alzheimers Disease. Medical Report with Composition of Medicaments - Light Green Pills, Injections and Syringe. Blurred Background with Selective Focus.

Access to the study drug for 12 weeks that may help manage agitation Alzheimer's patients.

Follow us on Twitter
Portrait of happy female patient showing thumbs up sign while standing with doctor in clinic

Close care and monitoring from an Alzheimer's Disease specialist.

Follow us on Twitter
Senior tourists using tablet on visiting journey

Reimbursement for study-related time and travel expenses.

Follow us on Twitter

What can study participants and their caregivers expect?

Study Duration Purpose of the Study Coordinating With Your Healthcare Provider

The Study Will Last 12 Weeks

The study will last for 12 weeks and you will be required to attend all study visits and complete all study procedures. By understanding the time commitment involved, you can plan accordingly and ensure you can commit to the study requirements.

Managing Agitation

The study aims to evaluate the safety and effectiveness of an investigational drug in managing agitation associated with Alzheimer's dementia. By participating, you could contribute to the advancement of medical research and help others in the future.

Make an Informed Decision

Remember, it is very important that both the participant and their caregiver attend all study visits and complete all study procedures. If you are considering participating in the study, talk to your healthcare provider and study coordinator to learn more about the study and if it is right for you.

Happy old couple smiling in a park on a sunny day

Take part in our Agitation in Patients With Dementia of Alzheimer's Type Phase 3 Study

 Recruiting

Sign up to see if you may qualify

Could you be part of the next Alzheimer's research breakthrough?

Research has changed the way we diagnose, treat, and understand Alzheimer's disease and it's made only possible because of people with Alzheimer's Disease who participated in clinical trials. Join us in learning better about the condition while participating in studies that will shape the future of Alzheimer's Disease and the thousands of people affected by it. 

Don't hesitate to contact us. 

Roxanne Cabading
Patient Engagement, SC3 Research Group

+1-6262502070 x 799
roxanne.cabading@neurosearch-usa.com
50 Bellefontaine St., Ste 203, Pasadena, CA 9110

Get Started